- Company
- Onivyde is expected to be eligible for insurance coverage
- by Eo, Yun-Ho Jul 16, 2021 05:54am
- The new pancreatic cancer drug Onivyde is expected to be listed on the insurance benefit. According to the industry, Servier recently concluded a negotiation with the NHIS for the listing of Onivyde(Irinotecan HCl). As a result, it is expected that new insurance benefits will be available in pancreatic cancer treatment. Onivyde is elig
- Company
- SMA tx Evrysdi has been applied for insurance benefits
- by Jul 16, 2021 05:54am
- Roche's Evrysdi, the second treatment for spinal muscular atrophy (SMA) in Korea, began the process of registering insurance benefits eight months after approval. According to the pharmaceutical industry on the 15th, Roche Korea applied to the HIRA earlier this month for the registration of the oral SMA treatment Evrysdi(Risdiplam). Evr
- Company
- Novartis most challenged for its patents, followed by Pfizer
- by Kim, Jin-Gu Jul 16, 2021 05:54am
- Among pharmaceutical companies, Novartis was found to have received the most amount of patent challenges since 2016. Over the past five and a half years, 33 generic companies had filed a total of 121 patent suits against Novartis' 15 patents on 8 products. In addition to Novartis, generic companies also targeted Pfizer, Boehringer Ingehei
- Company
- Xospata is approved as a targeted anti-cancer drug
- by Eo, Yun-Ho Jul 15, 2021 07:06pm
- The emergence of FLT3 targeted anticancer drugs is also causing new changes in the area of acute myeloid leukemia, which lacked treatment options. Chronic Myeloid Leukemia (CML), which was considered incurable, has benefited many patients from the commercialization of the targeted anti-cancer drug Glivec(Imatinib), but Acute Myeloid Leukem
- Company
- Keytruda overcomes its 4-year hurdle, with Tecentriq
- by Eo, Yun-Ho Jul 15, 2021 06:30am
- The immunotherapy ‘Keytruda’ finally overcame one giant hurdle for its reimbursement, with ‘Tecentriq.’ According to industry sources, the PD-1 inhibitors &8211; MSD Korea’s ‘Ketyruda (pembrolizumab) and Roche Korea’s ‘Tecentriq (atezolizumab)’ &8211; passed deliberations by the Health Insurance Review & Assessment Service’s C
- Company
- Will Rivoceranib+Iressa really be a game changer ?
- by Jul 14, 2021 06:26pm
- Can Rivoceranib+Iressa therapy really be a game changer? This is the title of the press release distributed by HLB on the 9th. "We have confirmed high synergy with the first-generation blockbuster EGFR TKI drug in phase 3 clinical trials," HLB said. "We expect a next-generation treatment due to a complete improvement in one person and PFS.
- Company
- Bavencio can be prescribed in general hospitals
- by Eo, Yun-Ho Jul 14, 2021 06:03am
- Merck and Pfizer’s immunotherapy ‘Bavencio’ can now be prescribed at general hospitals. According to industry sources, the PD-L1 inhibitor Bavencio (avelumab) passed the Drug Committees (DCs) of the Big-5s general hospitals in Korea - Seoul National University Hospital (SNUH), Asan Medical Center (AMC), Seoul St. Mary’s Hospital, Sams
- Company
- Will a new reimbursement model be introduced for Zolgensma?
- by Jul 14, 2021 06:03am
- The move to list Novartis’s new drug ‘Zolgensma (onasemnogene abeparvovec-xioi)’ for reimbursement benefits is now underway. The industry’s eyes are on which types of the RSA scheme will be combined for this ultra-high-priced ‘dream drug.’ Whether Zolgensma will be listed for insurance benefits is the focus of attention in the indus
- Company
- CKD-701 demonstrated the validity in phase III trials
- by Chon, Seung-Hyun Jul 14, 2021 06:03am
- Chong Kun Dang announced on the 12th that Lucentis’ biosimilar CKD-701 proved equivalent to the original drug in Phase 3 trials. Chong Kun Dang will apply to the MFDS for CKD-701. Lucentis, sold by Roche and Novatis, is a drug used to treat eye diseases such as wet age-related macular degeneration (AMD) and diabetic retinopathy. Lucentis' an
- Company
- Omipalisib is 200 times more effective than Remdesivir
- by Kim, Jin-Gu Jul 13, 2021 11:09pm
- Attention is focusing on Omipalisib, which was newly discovered by Korean researchers as a candidate material for COVID-19. In particular, as laboratory studies show that candidate substance is more than 200 times more effective than Veklury (Remdesivir), some are optimistic that it will be a "game changer" for the corona crisis. Some p
